Medical Device and Clinical Equipment Tenders in the NHS

NHS Supply Chain aggregates demand across trusts in defined product categories and runs competitions to appoint suppliers to those categories. Getting on a Supply Chain agreement does not guarantee volume. It gives you a compliant route through which a trust can buy, and the work of persuading individual trusts to switch to your product still sits with you afterwards. Suppliers who treat an award as the finish line are usually disappointed.

Framework agreements run by other bodies also serve device categories, and some trusts and procurement hubs run their own. A framework place is a licence to compete rather than a contract, and most frameworks then run call off competitions or direct awards against published criteria. Read the call off rules before you bid, because they tell you whether winning the framework gives you anything at all in practice.

Trust level procurement still happens, particularly for capital equipment, for products tied to a specific clinical service, and where a trust has a genuine local requirement that a national agreement does not meet. These competitions are smaller, more clinically driven and more sensitive to relationships with the department that will use the product.

The honest position is that not every route suits every supplier. A single product company with limited manufacturing capacity may be better served pursuing trust level and framework call off work than committing to a national agreement whose volume commitments it cannot meet. If that is your situation, say so at the outset rather than discovering it after award.

In most public sector tenders the evaluators are commercial and technical professionals scoring written answers against a published marking scheme. In device procurement the panel usually includes clinicians, and often a procurement lead, a clinical engineer or medical physics representative, an infection prevention lead and someone from the theatre or ward team that will actually use the product. Each brings a different question to the same submission.

Clinical evaluation tends to be practical. Panels want to know how the product behaves in use, what the learning curve looks like, what happens when something goes wrong at three in the morning, and whether the consumables and accessories are compatible with what the trust already holds. A written answer that is strong on regulatory conformity and silent on day to day use will lose marks it did not need to lose.

Many competitions involve a product evaluation, a trial, or a demonstration in the hospital. This is frequently where the decision is really made. The written submission gets you to the trial and a poor trial cannot be rescued by a good document, so treat the practical stage as part of the bid rather than an administrative step after it.

Commercial scoring still matters. Whole life cost, consumable pricing, service and maintenance terms and training provision are all in scope, and a low headline price attached to expensive consumables is usually seen through. Present cost in the terms the buyer has asked for and do not construct a pricing model they did not request.

Regulatory conformity for the UK market is the entry condition and its detail varies by device class and by the current position of the UK regulatory regime, which has been in transition. Requirements differ between competitions, so the tender documents and the regulator's own published guidance are the authority on what you must hold and when. Do not assume last year's tender pack is still accurate.

Beyond conformity, buyers ask for clinical evidence: published studies, post market surveillance data, real world use data and adverse event reporting. If the strongest data behind your product comes from outside the UK, say so plainly and explain what it does and does not demonstrate for an NHS population. Evaluators respond better to a clear account of the limits than to a claim that overreaches.

Quality management, traceability, recall procedures and field safety corrective action processes all get tested, as does supply resilience. Buyers now ask much harder questions about where a product is manufactured, how much stock sits in the UK, and what happens to continuity of supply if a route fails. A specific answer with numbers behind it beats a reassurance.

Training, installation, service response times and decommissioning come up repeatedly, particularly for equipment rather than consumables. So do information governance and cyber security where a device connects to a network or handles patient data, and the requirements there vary by trust and by the connection involved.

A specification for a device is usually written by or with the clinicians who will use it. If they have never seen your product, the specification will be shaped around what they do know, and you will spend the tender arguing that a different approach is equally valid. That is a difficult argument to win inside a scoring template.

Legitimate pre market engagement is a normal part of public procurement. Buyers run supplier days, market engagement events and prior information exercises precisely so that specifications are informed. Engaging at that stage is proper conduct, not an advantage taken. Engaging after a notice is published, outside the clarification process, is not, and suppliers get it wrong in both directions.

Practical engagement means getting your product in front of clinical teams through evaluation loans, professional bodies, conferences and peer published work, so that when a specification is drafted the people drafting it already understand what your device does. This is slow work measured in years rather than weeks, and it is the single biggest difference between device suppliers who win NHS business consistently and those who do not.

Where you have not done that work and a tender is imminent, be realistic. If the specification plainly describes a competitor's product and the evaluation weights features you do not have, the disciplined decision is often to sit that one out, raise clarifications that may improve the next iteration, and start the engagement that makes the following competition winnable.